From: Juvenile dermatomyositis: is periodontal disease associated with dyslipidemia?
Variables | JDM with gingivitis (GBI > 25%, n = 12) | JDM without gingivitis (GBI ≤ 25%, n = 12) | p |
---|---|---|---|
Demographic data | |||
Current age, years | 12.4 (8.3–18.4) | 9.2 (5.5–17.5) | 0.034 |
Age at disease presentation, years | 4.8 (3.7–7.4) | 5.2 (4.1–9.5) | 0.580 |
Disease duration, years | 7.09 ± 3.07 | 3.95 ± 2.1 | 0.008 |
Female gender | 9 (75) | 5 (41) | 0.182 |
Anthropometric data | |||
BMI, kg/m2 | 19.6 (14.5–30) | 19.2 (15.3–25) | 0.954 |
Body composition | |||
Fat percentual | 28.2 (11.1–45.4) | 26 (10.9–42) | 0.789 |
Fat mass, kg | 10.8 (5.0–27.1) | 8.2 (2.9–20.2) | 1.000 |
Lean mass, kg | 26.4 (15.4–43.8) | 27.2 (20–44.5) | 0.423 |
Lipid profile | |||
Total cholesterol | 151 (115–206) | 151 (102–227) | 0.913 |
≥ 170 mg/dL | 5 (41) | 3 (25) | 0.666 |
HDL, mg/dL | 43 (0–65) | 49 (17–72) | 0.328 |
≤ 45 mg/dL | 9 (75) | 4 (33) | 0.099 |
LDL, mg/dL | 92 (76–148) | 77.5 (56–129) | 0.265 |
≥ 130 mg/dL | 1 (9) | 0 | 1.000 |
VLDL, mg/dL | 16 (9–42) | 14.5 (9–68) | 0.957 |
Triglycerides, mg/dL | 82 (31–168) | 72.5 (46–340) | 0.935 |
≥130 mg/dL | 1 (8) | 3 (33) | 0.316 |
Anti-LPL antibody | 0 | 1 (8) | 1.000 |
Muscle enzymes | |||
AST, U/L | 28 (13–122) | 29.5 (15–82) | 0.703 |
ALT, U/L | 36 (22–123) | 34 (29–79) | 0.744 |
CK, U/L | 84 (33–478) | 125 (62–179) | 0.399 |
LDH, U/L | 184 (107–1234) | 216.5 (153–562) | 0.355 |
Aldolase, U/L | 5.7 (3.4–10.8) | 6.35 (4.6–14.6) | 0.231 |
Inflammatory profile | |||
ESR, mm/1SThour | 20 (2–40) | 19 (7–54) | 0.624 |
CRP, mg/dL | 0.59 (0.16–5.5) | 1.61 (0.15–26) | 0.242 |
JDM scores | |||
CMAS, 0–52 | 52 (10–52) | 52 (17–52) | 0.848 |
MMT, 0–80 | 80 (42–80) | 80 (38–80) | 0.742 |
DAS, 0–18 | 4 (0–12) | 3 (0–18) | 0.807 |
Cutaneous DAS, 0–9 | 1 (0–8) | 1 (0–9) | 0.663 |
Muscle DAS | 2 (0–9) | 2 (0–9) | 0.853 |
MYOACT, 0–1 | 0.05 (0–0.16) | 0.02 (0–0.3) | 0.724 |
MITAX, 0–1 | 0.01 (0–0.23) | 0 (0–0.28) | 0.462 |
CHAQ | 0 (0–1.75) | 0.625 (0–2.5) | 0.164 |
Treatment | |||
Prednisone | |||
Current use | 1 (8) | 8 (66) | 0.303 |
Cumulative dose, g | 13.6 (4.9–51.5) | 15.1 (3.9–31.2) | 0.531 |
Methotrexate | |||
Current use | 3 (25) | 8 (66) | 0.277 |
Cumulative dose, g | 2.2 (0.3–16.9) | 1.9 (0.37–4.98) | 0.79 |
Cyclosporine | |||
Current use | 0 | 3 (25) | 0.230 |
Cumulative dose, g | 0 (0–3.6) | 0 | 0.805 |